logo

OGN

Organon·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

OGN fundamentals

Organon (OGN) released its earnings on Nov 10, 2025: revenue was 1.60B (YoY +1.27%), beat estimates; EPS was 1.01 (YoY +16.09%), beat estimates.
Revenue / YoY
1.60B
+1.27%
EPS / YoY
1.01
+16.09%
Report date
Nov 10, 2025
OGN Earnings Call Summary for Q3,2025
  • Nexplanon Challenges: U.S. policy-driven 50% Q3 decline, flat 2026 outlook. Vtama Launch: 2026 access improvements needed for growth. Leadership Transition: Interim CEO focus on operational stability, CEO search underway.
  • Financial Discipline: 2025 guidance revised to $6.2B, deleveraging via Jada sale ($440M proceeds). Biosimilars Growth: Hadlima up 63% YoY, Tofidence launched Q3 2025.
EPS
Revenue

Revenue & Expenses

OGN has released its 2025 Q3 earnings report, with revenue of 1.60B, reflecting a YoY change of 1.26%, and net profit of 160.00M, showing a YoY change of -55.43%. The Sankey diagram below clearly presents OGN's revenue sources and cost distribution.

Key Indicators

Organon (OGN) key financial stats and ratios, covering profitability, financial health, and leverage.
Organon (OGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Organon (OGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Organon (OGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Organon (OGN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Organon (OGN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield